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Patients infected with human immunodeficiency virus type
1 (HIV-1) are considered to be at increased risk for 2009
H1N1 influenza–related complications. We performed an ob-
servational study after an outbreak of 2009 H1N1 influenza
virus infection among a group of 15 HIV-1–infected school-
aged children in Germany in October 2009. Clinical course,
kinetics of viral shedding, and antibody response among chil-
dren with CD4 cell counts 1350 cells/mL and 2009 H1N1
influenza virus coinfection did not appear to differ from that
among healthy children. Oseltamivir shortened the duration
of viral shedding.
In spring 2009, a new pandemic swine-origin influenza A
(H1N1) virus emerged in Mexico [1] and the United States [2]
and spread globally thereafter. Although the infection proved
to be uncomplicated in the majority of cases, severe compli-
cations and fatal outcomes have been reported. Risk factors
predictive for complications include younger age (children !2
years), pregnancy, obesity, pulmonary or other comorbid con-
ditions, and concurrent immunosuppression [3, 4]. On the
basis of data from seasonal influenza, it has been postulated
that patients infected with human immunodeficiency virus type
1 (HIV-1), especially those with low CD4 cell counts or ad-
vanced stage of disease, might be at increased risk for H1N1
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influenza–related complications [5, 6]. Data on the clinical
course of 2009 H1N1 influenza in HIV-1–infected children and
adolescents have not yet been published. We describe an out-
break of 2009 H1N1 influenza among a group of 15 HIV-1–
infected school-aged children in Germany, which allowed sys-
tematic monitoring of clinical features, kinetics of viral shed-
ding, and development of H1N1-specific antibodies in these
patients.
Methods. Fifteen perinatally HIV-1–infected children and
adolescents, all patients at the pediatric outpatient HIV clinic,
Charité, Berlin, Germany, participated in a 7-day trip to a youth
camp in Germany in October 2009. All were treated with highly
active antiretroviral therapy. Eleven patients (73%) had an HIV-
1 load !20 copies/mL, and all had CD4 counts 1350 cells/mL.
Comorbid conditions (mild asthma) were present in 2 children.
No patient had been vaccinated against 2009 H1N1 influenza
because the vaccine was not available at this time. Baseline
characteristics are summarized in Table 1.
On a second day of travel, a 16-year-old boy (patient I) had
to be hospitalized for high-grade fevers and cough, which ret-
rospectively was the first case of 2009 H1N1 influenza in the
group. On the last day of the trip, 3 children developed an
acute illness with high-grade fevers and influenza-like symp-
toms and subsequently received a diagnosis of 2009 H1N1 in-
fluenza virus infection by reverse transcriptase polymerase
chain reaction (RT-PCR) assay of nasal swabs. After parental
consent and approval by the institutional ethics committee, all
15 patients were closely monitored as outpatients.
Data on patients’ demographic characteristics and medical
history were obtained from review of medical records. Time
and quality of influenza-related symptoms at onset were doc-
umented as reported by patients and their camp supervisors.
During follow-up visits, scheduled every other day, disease
symptoms were recorded, physical examinations were per-
formed, and nasal swabs were collected and processed imme-
diately for virological analysis. After documentation of 2 con-
secutively negative RT-PCR results from nasal swabs,
monitoring and contact isolation at home were discontinued.
Virus isolation was performed on Madin-Darby canine kid-
ney SIAT-1 cells as described elsewhere [7]. Viral RNA was
extracted from nasal swabs, and the specific 2009 H1N1 influ-
enza RNA was amplified as described elsewhere [8]. 2009 H1N1
influenza–specific antibody titers of probes obtained ∼6 weeks
after the onset of symptoms were compared with those from
cryopreserved serum samples collected during routine clinic
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Table 1. Characteristics and Clinical Features of the 15 Human Im-





Sex, ratio female to male 7:8





CDC clinical and immunologic stagesa
Clinical stage N and A 4 (27)
Clinical stage B 5 (33)
Clinical stage C 6 (40)
Immunologic stage 1 1 (7)
Immunologic stage 2 7 (47)
Immunologic stage 3 7 (47)
CD4 cell count,b median cells/mL (range) 786 (371–1223)
HIV-1 load,b range copies/mL !20–7490
BMI, median value (range) 17.9 (14.8–21.9)
Symptoms of disease
Any symptom 14 (93)






Sore throat 2 (13)
Abdominal pain 2 (13)
Vomiting 1 (7)
Diarrhea 0 (0)
Dyspnea or respiratory distress 0 (0)
Duration of fever, median days (range) 1.5 (1–3)
Received antiviral treatment with oseltamivir 5 (33)
Received influenza vaccine during 2009–2010 season 7 (47)
NOTE. Data are no. (%) of children, unless otherwise indicated. BMI, body mass
index (calculated as weight in kilograms divided by the square of height in meters);
CDC, Centers for Disease Control and Prevention.
a CDC clinical stages of pediatric HIV-1 infection: N, no symptoms; A, mildly symp-
tomatic; B, moderately symptomatic; C, severely symptomatic; CDC immunologic
stage 1, no immunosuppression; stage 2, moderate immunosuppression; stage 3,
severe immunosuppression [21].
b Laboratory values prior to infection with 2009 H1N1 influenza virus.
by hemagglutination inhibition analysis using the 2009 H1N1
reference strain A/California/07/2009 and erythrocytes from
turkey hens. A hemagglutination inhibition titer of 1:10 was
considered to be a positive result.
Categorical variables were compared using the x2 test and
Fisher’s exact test, when appropriate. Continuous variables were
analyzed with the Mann-Whitney U test. All P values are 2-
tailed. Statistical significance was defined as .P ! .05
Results. 2009 H1N1 influenza infection was confirmed in
all 15 patients by cell culture ( ), RT-PCR from nasaln p 11
swabs ( ), or detection of 2009 H1N1–specific antibodiesn p 11
in serum ( ). This resulted in an attack rate of 100%.n p 14
Fourteen of 15 patients became symptomatic, all within a 7-
day period. The most common symptoms were fever, cough,
and fatigue (Table 1). Mild symptoms, mostly low-grade fevers
(138C to 39C) for !24 h and cough, occurred in 8 children.
Five patients, who presented with high-grade fever (139C),
































A 13.7 F Black 703 497 No 39.0 Cough, fatigue No No !10 1:10
B 16.7 M White 923 Negative No 39.4 Cough, fatigue, headache, myalgia Yes No !10 1:160
C 14.4 M Asian 687 Negative No 38.6 Cough, fatigue No No !10 1:40
D 8.9 F White 786 Negative No 40.0 Cough, fatigue, myalgia, abdominal pain Yes No !10 1:20
E 15.0 M Black 1223 186 No NA No symptoms reported No No !10 1:80
F 13.3 F Black 1116 !20 No NA Headache, sore throat No No !10 1:40
G 15.9 M Black 672 Negative Asthma 38.9 Cough, fatigue No No !10 1:40
H 12.7 F White 654 577 No NA Cough, fatigue, myalgia No No !10 1:40
I 16.8 M Black 371 7490 No 40.0 Cough, fatigue, chest pain, chill, head-
ache, myalgia
No Severe HSV stomatitis !10 1:40
J 8.9 F Black 840 Negative No 39.6 Cough, fatigue, headache, nausea, ab-
dominal pain, vomiting
Yes No !10 1:40
K 12.0 M Black 1106 !20 No 39.1 Cough, fatigue, rhinorrhea, myalgia Yes No !10 1:20
M 13.8 M Black 917 Negative No NA Cough, headache, rhinorrhea No No !10 1:320
N 11.4 M White 991 Negative No 38.5 Cough, fatigue, headache No No !10 1:160
O 10.3 F White 676 !20 No 39.1 Cough, headache, sore throat, fatigue Yes No N/A N/A
P 12.8 F White 588 Negative Asthma NA Cough, headache, sore throat No No !10 1:40
NOTE. HIT, hemagglutination inhibition antibody titer to influenza virus; HIV-1, human immunodeficiency virus type 1; HSV, herpes simplex virus; NA, not applicable; N/A, not available.
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within 48 h after onset of symptoms. Because of initial concerns
about severe disease in this patient population, oseltamivir was
given for 7 days instead of the 5 days recommended. The med-
ication was administered twice daily with weight-based dosing
according to the manufacturer’s instructions. In all treated pa-
tients, fever resolved within 24 h, and adverse effects were not
observed. Patient I was hospitalized for 8 days prior to the
diagnosis of 2009 H1N1 influenza and did not receive neur-
aminidase inhibitor treatment. No other patient was hospital-
ized or received antibiotics for bacterial superinfection. Further
details on individual patients are summarized in Table 2.
Blood cell counts during influenza infection were available
in 6 patients. Even though 5 patients had a transient neutro-
penia (!1500 neutrophils/mL), severe lymphopenia (800 lym-
phocytes/mL) was not observed.
Nasal swabs were available from all 15 patients; the first
specimen was collected at a median of 3 days (range, 1–9 days)
after onset of symptoms. Initial samples from 11 patients (73%)
had positive results by RT-PCR; all of them also had positive
culture results. The median time from onset of symptoms to
first negative RT-PCR result was 9 days (range, 5–14 days),
whereas culture results became negative after 6 days (range, 3–
11 days). Four patients who had negative results by RT-PCR
also had negative results by culture.
Because of more severe initial symptoms, 5 patients received
antiviral therapy with oseltamivir. There was a significant dif-
ference in the duration of viral shedding in oseltamivir-treated
versus untreated patients; among oseltamivir-treated children,
2009 H1N1–specific RNA was detected for a median of 4 days
(range, 4–5 days), compared with 8 days (range, 8–13 days)
among untreated patients ( ). Virus was detectable byP p .005
culture for a median of 3 days (range, 2–3 days) among os-
eltamivir-treated patients, compared with 6 days (range, 5–10
days) among untreated patients ( ).P p .005
Comparative serum samples were available for 14 patients.
Although all baseline probes were antibody negative, all follow-
up samples had positive results (median titer, 1:40; range, 1:
10 to 1:320), including samples from patients who had negative
results by RT-PCR or culture. Eleven (79%) of 14 patients had
an antibody titer of 1:40 (Table 2).
Discussion. All 15 participants in a travel group of HIV-
1–infected school-aged patients were found to be infected with
2009 H1N1 influenza virus, which emphasizes the high level
of contagiosity of the virus in this setting. This observation is
in contrast to the relatively low transmissibility of the 2009
H1N1 influenza virus reported among immunocompetent
household contacts [9] and may be explained by the very close
contact of the children during the trip. According to current
Centers for Disease Control and Prevention guidelines, patients
with HIV-1 infection or other forms of immunodeficiency are
considered to be at risk for complications of 2009 H1N1 in-
fluenza [10]. However, our observations revealed a mostly self-
limited and mild clinical course with clinical features similar
to those reported in the general pediatric population [4, 11,
12]. Relatively few patients in our cohort had fever (10 [67%]
of 15 children), compared with the incidence reported among
mostly immunocompetent children with 2009 H1N1 influenza
(88% [12] to 95% [11]). This may be explained by the fact
that these studies included mostly hospitalized patients. Severe
lymphopenia (800 lymphocytes/mL), which may be a pre-
dictor for respiratory failure [13], was not observed among our
patients.
The benign clinical course in this HIV-1–infected population
may be explained by the lack of severe immunodeficiency at-
tributable to successful antiretroviral treatment, the absence of
relevant comorbidities, and in light of an underlying chronic
disease, increased awareness by patients and care providers,
leading to earlier diagnosis and intervention.
Studies of seasonal influenza [14] and 2009 H1N1 influenza
[15] have indicated that viral shedding might be prolonged in
immunocompromised patients. Aside from an anecdotal report
[16], very little is known about the duration of viral shedding
after influenza infection in HIV-1–infected patients. In our co-
hort, viral shedding lasted a median of 8 and 5 days, measured
by RT-PCR and culture, respectively, which was similar to pub-
lished reports in general populations [17, 18]. Because early
antiviral treatment with oseltamivir resulted in a significantly
shorter duration of viral shedding, this treatment may not only
mitigate symptoms but may also reduce transmissions to sus-
ceptible household members who may be at increased risk of
complications (eg, because of HIV-1 infection with advanced
immunodeficiency) [19].
It has been hypothesized that immunocompromised patients
may not develop protective immunity after 2009 H1N1 influ-
enza infection. In our study group, all patients tested developed
2009 H1N1–specific antibodies. Whether this confers long last-
ing protection remains to be determined. However, 11 of 14
patients had a hemagglutination inhibition antibody titer of
1:40, which is considered to be protective in vaccine studies
[20].
In conclusion, the clinical course of 2009 H1N1 influenza
among HIV-1–infected school-aged children with CD4 counts
1350 cells/mL receiving highly active antiretroviral therapy did
not differ from that described for healthy children. Viral shed-
ding was not prolonged and could be further shortened by
early neuraminidase inhibitor treatment, and the humoral im-
mune response seems to be preserved. However, the same may
not apply for HIV-1–infected patients with advanced immu-
nodeficiency and/or comorbid conditions and for those living
in areas with restricted access to medical care. Therefore, in
accordance with current recommendations, HIV-1–infected pa-
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infection, an empirical early antiviral treatment is strongly ad-
vised.
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